nomida semaglutide Novo Nordisk is proactively protecting its weight loss drugs from copycats Novo Nordisk medicines containing semaglutide

Real-World Examples: 250-Pound Person: Average loss: 56 pounds (22.5%) Final weight: 194 pounds Timeline: 18-20 months 200-Pound Person: Average loss: 45 pounds (22.5%) Final weight: 155 pounds Timeline: 18-20 months 300-Pound Person: Average loss: 67 pounds (22.5%) Final weight: 233 pounds Timeline: 20-24 months Dosing Schedule: Standard Escalation: Weeks 1-4: 2.5 mg weekly (starting dose) Weeks 5-8: 5 mg weekly Weeks 9-12: 7.5 mg weekly Weeks 13-16: 10 mg weekly (if tolerating well) Weeks 17-20: 12.5 mg weekly (if needed) Week 21+: 15 mg weekly (maximum dose for weight loss) Flexible Dosing: Not everyone needs maximum 15 mg dose Many achieve excellent results at 10 mg Provider adjusts based on results and tolerance Can stay at effective dose rather than pushing to maximum Side Effects: Most Common: Nausea: 30-37% (lower than semaglutide despite higher potency) Diarrhea: 19-23% Vomiting: 9-17% Constipation: 10-17% Abdominal discomfort: 8-11% Interesting Finding: Despite being more potent, tirzepatide causes less nausea and vomiting than semaglutide

It is an FDA-approved formulation of semaglutide specifically indicated for weight loss in individuals with qualifying BMI ranges or obesity-related comorbidities

Ongoing large-scale prospective studies and post-marketing surveillance are needed to further refine risk estimates and inform evidence-based clinical guidance for patients at higher baseline risk

Curr Med Chem.2012;19(14):2104-2127

Paz-Filho et al., 2011)

The correct dose, dose escalation schedule and safety monitoring requirements may change if retatrutide is approved in the future